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Abstract: Ovarian primary mucinous adenocarcinomas (MACs) are refractory to conventional therapy. Biomarkers 
for ovarian MAC could facilitate prognosis and targeted therapy, but are not currently available. The expression of 
human epidermal growth factor 2 (HER-2) has been linked to enhanced survival of MAC patients and may hold 
potential as a biomarker, but this potential has not been sufficiently investigated. In this study, we examined the 
clinicopathological features of 46 cases of MAC and 36 cases of patients with mucinous borderline tumors (MBTs). 
The expression of estrogen receptors (ER), progesterone receptors (PR), and HER2 were measured by immunohis-
tochemistry and fluorescent in situ hybridization (FISH). Next, we compared the clinicopathological characteristics 
according to the HER2 expression profile. MBTs of the endocervical type tended to have simultaneous ER and PR 
expression (P = 0.0028) while MACs rarely showed ER or PR expression. HER2 expression was observed in 14 out of 
the 46 MACs (37.84%) and in none of the MBTs (P = 0.0002). HER2-positive MACs occurred approximately 10 years 
earlier than HER2-negative MACs (35.21 ± 4.768 years compared to 46.78 ± 1.977 years; P = 0.0105). All HER2-
positive MACs demonstrated an expansile invasive pattern, while all MACs with infiltrative invasion pattern were 
HER2-negative (P = 0.0406). Kaplan-Meier survival analysis demonstrated a tendency for improved overall survival 
in HER2-positive MACs compared to HER2-negative MACs (P = 0.0389). In conclusion, HER2 overexpression in 
ovarian MACs is associated with an expansile, but not an infiltrative, invasion pattern and a favorable prognosis. 
Therefore, we suggest that HER2 may be a practical marker for histopathological categorization and a prognostic 
marker in ovarian MACs. 
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Introduction
Approximately 30% of cancers of the female 
genital tract are ovarian, and in North America 
and Western Europe, 90% of these are surface 
epithelial-stromal tumors [1]. Mucinous neo-
plasm is the second most common subcatego-
ry of surface epithelial-stromal tumors. This 
subcategory consists of a spectrum of types: 
benign mucinous cystadenoma, mucinous bor-
derline tumor (MBT) with low malignant poten-
tial, and mucinous adenocarcinoma (MAC). 
Although mucinous cystadenoma is the most 
common ovarian mucinous neoplasm compris-
ing 14% of all ovarian neoplasms, ovarian MBT 
and MAC are less numerous than their serous 
counterparts comprising 1% of all ovarian neo-
plasms in each [2]. 80% of MBTs are confined 
to the ovaries and they have a favorable prog-
nosis even in advanced stages showing over 
90% survival rate [3-6]. On the contrary, ovarian 
MAC is known to be highly aggressive because 
most patients will already have extra-pelvic 
metastasis at diagnosis and it shows a high 
recurrent rate even after invasive treatment [7, 
8]. 
Currently, few biomarkers of ovarian cancer are 
available. Although several studies have shown 
estrogen receptor (ER) and progesterone recep-
tor (PR) expression in ovarian tumors, their clini-
cal significance in terms on survival and/or 
prognosis remains controversial [9-13]. In stud-
ies of breast cancer, the expression of human 
epidermal growth factor 2 (HER2) is routinely 
assessed, as it is a well-known marker for 
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aggressive behavior of the tumor. It is also use-
ful because it can be targeted by adjuvant 
immunotherapy [14-16]. A study adopting 
monoclonal humanized anti-HER2 antibody 
described HER2 over-expression in recurrent or 
refractory ovarian carcinomas [17]; however, 
this study was not focused on primary sponta-
neous MACs.
Recently, HER2 overexpression and/or amplifi-
cation was described in some ovarian MACs, in 
which subset were nearly exclusive of KRAS 
mutations. This suggests that either HER2 
amplification/overexpression and/or KRAS mu- 
tations were associated with decreased likeli-
hood of disease recurrence or death [18, 19]. 
However, it is difficult to explain why HER2-
positive MACs were associated with favorable 
outcomes considering the fact that HER2-
positive breast cancers show aggressive beha- 
vior. 
In this study, we examined the status of ER, PR, 
and HER2 in ovarian tissues of patients with 
MBT and MAC, according to their histological 
subtypes. The relevance of these markers to 
factors related to the prognosis of patients with 
primary MAC was also assessed.
Materials and methods
Case selection
This retrospective study was approved by the 
institutional review board of Yonsei University 
Medical Center (IRB no. 4-2014-0034). Our 
study population consisted of 36 patients with 
MBT and 46 patients with MAC; all consecutive 
patients who had undergone treatment at 
Yonsei University Medical Center from 2001 to 
2012.
The patients’ tissue samples were fixed in 10% 
buffered formalin and embedded in paraffin. 
Archival tissues stained with hematoxylin and 
eosin (H&E) were reviewed by two obstetrics 
and gynecology pathologists (SK Kim and NH 
Cho). Patients’ clinical characteristics included 
age at initial diagnosis, International Federation 
of Gynecology and Obstetrics (FIGO) stage, 
adjuvant chemotherapy, and survival. All the 
patients who had received adjuvant chemo-
therapy had been treated with paclitaxel and 
platinum regimen.
Tissue microarray
A representative area was selected on an H&E-
stained tissue slide, and the corresponding 
area was marked on the surface of the corre-
sponding paraffin-embedded tissue block. We 
used 5-mm sized tissue core because muci-
nous neoplasms usually have variable amounts 
of mucin materials. The selected area was 
punctured using a biopsy needle, and a 5-mm 
tissue core was extracted and transferred onto 
a 5 × 4 recipient block. Each tissue core was 
assigned a unique tissue microarray location 
number that was linked to a database record 
containing other clinicopathological data.
Immunohistochemistry
Antibodies used were as follows. The antibody 
to ER was from Thermo Scientific, San Diego, 
CA, USA (clone SP1, dilution rate of 1:100). The 
antibody to PR was from DAKO, Glostrup, 
Denmark (clone PgR, dilution rate of 1:50). The 
antibody to HER2 was acquired from Ventana 
medical systems, Tucson, AZ, USA (monoclonal, 
antibody concentration of 6 μg/ml). Immuno- 
histochemistry (IHC) was performed using for-
malin-fixed, paraffin-embedded (FFPE) tissue 
sections. Briefly, 5-μm-thick sections were cut 
using a microtome, transferred onto adhesive 
slides, and dried at 62°C for 30 minutes. After 
incubation with primary antibodies, IHC was 
performed using a Dako Envision Kit or 
BenchMark XT staining system (Ventana medi-
cal systems) following the manufacturers’ 
instructions. Slides were counterstained with 
Harris hematoxylin.
Interpretation of immunohistochemical stain-
ing
A cut-off value of >1% of nuclei that were 
strongly stained was used to define expression 
of ER and PR [20]. HER2 staining was analyzed 
according to guidelines by the American Society 
of Clinical Oncology (ASCO)/College of American 
Pathologists (CAP). These guidelines are as fol-
lows: a value of 0 represents no immunostain-
ing; 1+, weak incomplete membranous staining 
of <10% of tumor cells; 2+, complete membra-
nous staining, either uniform or weak, of ≥10% 
of tumor cells; and 3+, uniform intense mem-
branous staining of ≥30% of tumor cells [21]. 
HER2 immunostaining was considered positive 
when strong (3+) membranous staining was 
observed, while values of 0 to 1+ were consid-
ered negative. Tissues that had staining values 
of 2+ were further examined by fluorescent in 
situ hybridization (FISH) for HER-2 amplifi- 
cation. 
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FISH 
FISH was performed on tumor sections after 
examination by H&E microscopy. A PathVysion 
HER-2 DNA Probe Kit (Vysis, Downers Grove, IL, 
USA) was used according to the manufacturer’s 
instructions. The copy number of HER-2 on the 
slides was evaluated using an epifluorescence 
microscope (Olympus, Tokyo, Japan). At least 
60 tumor cell nuclei in three separate regions 
were investigated for HER-2 and chromosome 
17 signals. HER-2 gene amplification was deter-
mined according to the ASCO/CAP guidelines 
[21].
Statistics
Statistical analyses were performed using 
GraphPad Prism 5 software, version 5.01 
(GraphPad Software, Inc., La Jolla, CA, USA) 
and SPSS for Windows, version 12.0 (SPSS 
Inc., Chicago, IL, USA). For the analysis of age at 
diagnosis, a significant difference between 
means was determined by t-test. FIGO stage; 
invasion pattern; and expression of ER, PR, and 
HER2 in ovarian mucinous neoplasms were 
compared by Chi-square and Fisher’s exact. 
stages III and IV. Most of the cases with MBT 
were at the localized stage: 34 out of 36 cases 
(94.44%), while more of the cases with MAC 
were advanced. 22 cases of MAC out of 46 
were in the localized stage (47.83%), while 14 
cases were in the regional stage (30.43%), and 
10 cases were in the distant stage (21.74%).
For further characterization of the pathologic 
features, we categorized MBTs and MACs into 
two groups according to their tumor cell types 
and invasion patterns. MBTs could be classified 
according to their mucinous cell types, which 
are MBT of intestinal type or endocervical type 
[1]. Among the 36 MBTs, 30 were intestinal 
type (83.33%) and 6 were endocervical type 
(16.67%) which profile was similar to a previous 
report which described intestinal type to 
account for 85-90% of MBTs [1]. MACs differ 
from MBTs in that they demonstrate stromal 
invasion. Features such as complex glandular 
proliferation (defined as expansile invasive pat-
tern) or infiltrative glands/tubules (defined as 
infiltrative invasive pattern) are considered as 
evidence of invasion [1]. Among the 46 cases of 
MAC studied here, 37 had the expansile inva-
Table 1. Clinicopathologic features of MBT and MAC ovarian 
mucinous tumors
MBT MAC P-value
Number of cases 36 46
Age at diagnosis 44.36 ± 2.502 43.26 ± 2.122 0.7369
Follow-up (months) 55.08 ± 6.053 51.13 ± 5.184 0.6199
Stage at diagnosis <0.0001
    Localized (FIGO IA, IB) 34 22
    Regional (FIGO IC, II) 2 14
    Distant (FIGO III, IV) 0 10
Histological type (%)
    Intestinal 30 (83.33) NA
    Endocervical 6 (16.67) NA
Invasion pattern (%)
    Expansile NA 37 (80.43)
    Infiltrative NA 9 (19.57)
ER positive (%) 6 (16.67) 1 (2.17) 0.0398
    Intestinal 0 (0.00) NA 0.0002
    Endocervical 6 (100.00) NA
PR positive (%) 3 (8.33) 0 (0.00) 0.0806
    Intestinal 0 (0.00) NA 0.0028
    Endocervical 3 (50%) NA
HER2 positive (%) 0/36 (0) 14/46 (37.84) 0.0002
NA, not applicable.
Kaplan-Meier survival curves and 
log-rank statistics were employed 
to evaluate overall survival. Univa- 
riate and multivariate regression 
analysis was performed using Cox 
proportional hazards model. 
Results
Clinicopathological features of 
ovarian mucinous neoplasms
First, we examined the clinical 
characteristics of patients with 
ovarian mucinous neoplasms 
(Table 1). There was no significant 
difference in the median age at 
diagnosis of patients with MBT (n = 
36, 44.36 ± 2.502 years) and MAC 
(n = 46, 43.26 ± 2.122 years, P = 
0.7369). We grouped cases of 
mucinous neoplasms based on the 
stage of the tumor at diagnosis 
according to the following criteria. 
The localized stage encompassed 
the FIGO stages IA and IB, the 
regional stage corresponded to 
FIGO stages IC and II, and the dis-
tant stage corresponded to FIGO 
HER2-positive ovarian mucinous adenocarcinoma
4225 Int J Clin Exp Pathol 2014;7(7):4222-4230
sive pattern (80.43%) and the remaining nine 
had the infiltrative invasive pattern (19.57%).
Next, we performed immunohistochemistry to 
determine the ER and PR status of each tumor 
(Figure 1A and Table 1). ER and PR were rarely 
or not expressed in the 46 ovarian MACs. Only 
one tumor (2.17 %) expressed ER, while none 
expressed PR. In contrast, in the 36 MBT 
tumors, six expressed ER (15.67%) and three 
expressed PR (8.33%); the differences were 
significant (P = 0.0398 and 0.0806 for the 
comparison of ER and PR expression in the two 
types of tumors, respectively). All six MBT 
tumors of the endocervical type expressed ER 
(P = 0.0002) as described in a previous study 
[22]. PR expression was confined to MBT 
tumors of endocervical type (3 tumors out of 
36, 8.33%). Three tumors out of the six (50%) 
that expressed ER also expressed PR and it 
means that ER expression was significantly cor-
related with PR expression (P = 0.0028). 
Figure 1. HER2 expression profiles of ovarian mucinous borderline tumors (MBTs) and mucinous adenocarcinomas 
(MACs). A. Representative histological pictures of MBTs of the intestinal type (top lane, first column) and the endo-
cervical type (second lane, first column) and MACs with the expansile invasive pattern (third lane, first column) and 
the infiltrative invasive pattern (bottom lane, first column). Immunohistochemical staining results for ER (second 
column), PR (third column), and HER2 (fourth column) performed in MBTs and MACs. Scale bar = 100 μm. B. Rep-
resentative pictures of FISH assay for HER2 amplification. Centromere of chromosome 17 represented by a green 
signal and HER-2 gene represented by an orange signal. (Magnification = 1,000 ×).
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sion patterns of MACs on the whole slide and 
categorized them according to their expression 
of HER2. All the HER2-positive MACs demon-
strated an expansile invasive pattern (14 out of 
Next, we assessed the HER2 status using 
immunohistochemical staining and FISH analy-
sis in MBTs and MACs (Figure 1A and 1B) [23]. 
HER2 overexpression or amplification was not 
Table 2. Comparison of clinicopathological features of ovarian 
MAC according to HER2 expression
HER2-negative HER2-positive P-value
Case number 32 14
Age at diagnosis (years) 46.78 ± 1.977 35.21 ± 4.768 0.0105
Follow-up (months) 47.06 ± 5.769 60.43 ± 10.71 0.2397
Vital status 0.0389
    Alive 17 10
    Died 8 0
    Follow-up loss 5 4
Stage at diagnosis 0.3344
    Localized (FIGO IA, IB) 13 9
    Regional (FIGO IC, II) 11 3
    Distant (FIGO III, IV) 8 2
Adjuvant chemotherapy (%) 23 (71.88) 7 (50.00) 0.1886
Invasion pattern (%)
    Expansile 23 14 0.0406
    Infiltrative 9 0
Figure 2. Survival analysis of patients with MAC according to their HER2 
status. A. Overall survival of MAC patients according to their HER2 status. 
B. Disease-free survival relative to HER2 status.
apparent in any of the MBTs, but 
14 of the 46 MACs (37.84%) had 
increased levels of HER2 expres-
sion (P = 0.0002). The number of 
MAC tumors exhibiting overex-
pression was higher than has 
been previously reported [18, 19, 
24].
Clinicopathological characteris-
tics of HER2-positive MACs com-
pared to HER2-negative MACs
Next, we attempted to compare 
the clinical and histopathological 
features of MACs according to 
their HER2 expression (Table 2). 
Several clinicopathological para- 
meters believed to be associated 
with the survival of the MAC 
patients were assessed. These 
included age, tumor stage, adju-
vant chemotherapy, and the inva-
sive pattern. 
In our study population, HER2-
positive MACs were diagnosed 
approximately 10 years earlier 
(35.21 ± 4.768 years) than HER2-
negative MACs (46.78 ± 1.9777 
years, P = 0.0105). There was no 
significant difference in the stage 
of the tumor at diagnosis between 
HER2-positive and HER2-nega- 
tive patients (P = 0.3344). Adju- 
vant chemotherapy after oopho-
rectomy had been performed at a 
similar rate in both groups of 
patients (P = 0.1886).
It is well known that the current 
grading system of mucinous car-
cinomas can predict neither the 
tumor behavior nor treatment 
response [1, 24, 25]. However, 
the occurrence of infiltrative stro-
mal invasion has been proven to 
represent a more aggressive bio-
logical feature in comparison 
with expansile invasion [1]. 
Therefore, we examined the inva-
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survival (Table 3). When we used multivariate 
analysis to adjust variables that might affect 
survival, advanced age at diagnosis (Hazard 
ratio: 1.090, 95% CI: 1.025-1.158, P = 0.006) 
and the infiltrative invasive pattern (Hazard 
ratio: 4.818, 95% CI: 1.147-20.242, P = 0.032) 
were associated with worse overall survival 
(Table 4). On the other hand, advanced age at 
diagnosis (Hazard ratio: 1.098, 95% CI: 1.042-
1.158, P = 0.001) and a distant tumor stage 
(Hazard ratio: 7.104, 95% CI: 1.328-38.005, P 
= 0.022) decreased disease-free survival, how-
ever, HER2 positivity (Hazard ratio: 0.109, 95% 
CI: 0.012-0.965, P = 0.046) improved disease-
free survival. 
Discussion
Ovarian MAC is a highly aggressive tumor with a 
5-year survival rate of only 10-30% even if the 
patients receive platinum-taxane based che-
motherapy after aggressive surgery [8, 26-28]. 
46) whereas all MACs showing infiltrative inva-
sive pattern were HER2-negative (9 out of 46, P 
= 0.0406) (Figure 1 and Table 2).
HER2-positive MACs with a favorable outcome
We speculated that HER2 overexpression in 
MACs might be associated with a favorable 
prognosis, as it seemed to be correlated with 
the less aggressive expansile invasive pattern. 
We collected follow-up data of MAC patients 
and performed Kaplan-Meier survival analysis 
to compare the HER2-positive to the HER2-
negative groups (Table 2 and Figure 2). Mean 
follow-up duration for MAC patients was 47.06 
± 5.769 months for HER2-negative patients 
and 60.43 ± 10.71 months for HER2-positive 
patients and the follow-up time between the 
two groups was not significantly different (P = 
0.2397). 
Patients with the HER2-positive MACs have had 
a relatively favorable outcome compared with 
Table 3. Univariate analysis of overall survival and disease-free survival in patients with ovarian MAC
Predictor variable
Overall survival Disease-free survival 
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age at diagnosis 1.090 1.025-1.158 0.006 1.098 1.042-1.158 0.001
Invasive pattern 
    Expansile versus Infiltrative 3.845 0.959-15.410 0.057 3.301 1.006-10.828 0.049
Stage at diagnosis 0.038 0.005
    Localized versus regional 0.742 0.066-8.294 0.6809 1.459 0.205-10.363 0.706
    Localized versus distant 5.839 1.131-30.138 0.035 9.292 1.924-44.880 0.006
HER2 status 
    Negative versus positive 0.025 0.000-11.142 0.235 0.199 0.025-1.562 0.125
Adjuvant chemotherapy 3.054 0.375-24.873 0.297 5.369 0.387-41.953 0.109
Table 4. Multivariate analysis of overall survival and disease-
free survival in patients with ovarian MAC
Predictor variable
Overall survival
Hazard ratio 95% CI P-value
Age at diagnosis 1.090 1.025-1.158 0.006
Invasive pattern
    Expansile versus Infiltrative 4.818 1.147-20.242 0.032
Predictor variable
Disease free survival
Hazard ratio 95% CI P-value
Age at diagnosis 1.098 1.042-1.158 0.001
Stage at diagnosis 0.009
    Localized versus regional 0.912 0.123-6.749 0.928
    Localized versus distant 7.104 1.328-38.005 0.022
HER2 status 
    Negative versus positive 0.109 0.012-0.965 0.046
that of HER2-negative MACs when 
overall survival is considered 
(Figure 2A, P = 0.0389). This 
result agrees with a previous 
report, in which it was concluded 
that HER2 amplification or overex-
pression was associated with a 
lower risk of disease recurrence 
and death [18]. 
Next, we conducted a statistical 
analysis to find the effect of pre-
dictor variables on the survival of 
ovarian MAC patients. In univari-
ate analysis, age at diagnosis, 
invasive pattern, and the tumor 
stage at diagnosis were statisti-
cally significantly associated with 
overall survival and disease-free 
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all survival in patients with HER2-positive MAC 
compared to patients with HER2-negative MAC 
(P = 0.0389). When we adjusted variables that 
could affect disease-free survival using multi-
variate analysis, HER2 positivity was consid-
ered to be a valid marker for prediction of out-
come (Hazard ratio: 0.109, 95% CI: 0.012-
0.965, P = 0.046).
In conclusion, HER2-positive MACs tend to 
have early disease onset, an expansile invasive 
pattern, and a favorable prognosis. Therefore, 
we suggest that the HER2 protein could be uti-
lized as a biomarker to predict the prognosis of 
MAC patients and could be useful in classifying 
the molecular subtype of ovarian mucinous 
neoplasm. 
Acknowledgements 
We thank Dr. Eun Ji Nam for contributing of clin-
ical data. This work was supported by the 
grants from the the Basic Science Research 
Program through the National Research 
Foundation of Korea (NRF) funded by the Mid-
career Researcher Program (No. 2012R1A2A- 
4A01006435; CNH).
Disclosure of conflict of interest
None.
Address correspondence to: Dr. Nam Hoon Cho, 
Department of Pathology, Yonsei University College 
of Medicine, Seodaemun-Gu, Shinchon-Dong 134, 
Seoul, Korea 120-752. Tel: +82-2-2228-6752; Fax: 
+82-2-362-0860; E-mail: CHO1988@yuhs.ac
References
[1] Kikkawa F, Kawai M, Tamakoshi K, Suganuma 
N, Nakashima N, Furuhashi Y, Kuzuya K, 
Hattori S, Arii Y and Tomoda Y. Mucinous carci-
noma of the ovary. Clinicopathologic analysis. 
Oncology 1996; 53: 303-307.
[2] Zaloudek CF. Diagnostic Histopathology of 
Tumors. Philadelpiha, USA: Elsevier; 2007.
[3] Kaern J, Trope CG and Abeler VM. A retrospec-
tive study of 370 borderline tumors of the ova-
ry treated at the Norwegian Radium Hospital 
from 1970 to 1982. A review of clinicopatho-
logic features and treatment modalities. 
Cancer 1993; 71: 1810-1820.
[4] Russell P and Merkur H. Proliferating ovarian 
“epithelial” tumours: a clinico-pathological 
analysis of 144 cases. Aust N Z J Obstet 
Gynaecol 1979; 19: 45-51.
Recent studies suggest that ER or PR can be 
used as biomarkers in some ovarian cancers to 
predict survival [9-13]. However, the validity of 
these markers in prognosis of ovarian MACs is 
unclear. Consistent with a previous report [22], 
we observed that MBTs of the endocervical 
type tend to have simultaneous expression of 
both ER and PR while MACs rarely expressed 
either of these receptors. Also, in this study, PR 
expression was confined to MBTs of the endo-
cervical type while ER expression correlated 
with PR expression
HER2 overexpression or amplification was iden-
tified only in MACs in this study. This result 
agrees with previous in vitro experiments, 
which suggest that HER2 signaling regulated by 
the mucin 4 protein (MUC4) is involved in malig-
nant transformation and invasion in ovarian 
cancers [29-32]. Recently, McAlpine et al. 
reported that amplification of HER2 was 
observed in 18.8% of MBTs and 18.2% of MACs 
[19]. In another study, Angleio et al. observed 
the occurrence of overexpression of HER2 in 
6.2% of MBTs and 18.8% of MACs [18]. In our 
study, the frequency of HER2 positivity in MACs 
was much higher (37.84%). We believe that this 
discrepancy could reflect differences in the 
patient population, as a large cohort study of 
Asian patients similarly reported a higher fre-
quency of HER2-positive MACs than that of 
Western patients [24]. We also noticed that the 
HER2-positive MACs occurred approximately 
10 years earlier than HER2-negative MACs (P = 
0.0105).
We hypothesize that the HER-2 status is related 
to prognosis. This hypothesis is supported by 
our comparison of invasion patterns of MAC 
and the HER2 expression profile. Infiltrative 
stromal invasion pattern of MAC is known to be 
biologically more aggressive than expansile 
invasion pattern [1]. We assessed the invasion 
patterns of MACs, and matched them with the 
HER-2 expression profile. Of note, all HER2-
positive MACs demonstrated an expansile inva-
sive pattern, and HER2-negative MACs more 
frequently showed an infiltrative invasive pat-
tern (P = 0.0406). Therefore, we inferred that 
HER2 expression could be associated with a 
favorable prognosis in MAC patients.
When we performed Kaplan-Meier analysis 
according to the HER2 expression status, we 
observed statistically significant superior over-
HER2-positive ovarian mucinous adenocarcinoma
4229 Int J Clin Exp Pathol 2014;7(7):4222-4230
Jimenez-Linan M, Driver K, Alsop J, Mack M, 
McGuire V, Rothstein JH, Rosen BP, Bernardini 
MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, 
Gentry-Maharaj A, Gayther SA, Tinker AV, 
Prentice LM, Chow C, Anglesio MS, Johnatty 
SE, Chenevix-Trench G, Whittemore AS, 
Pharoah PD, Goode EL, Huntsman DG and 
Ramus SJ. Hormone-receptor expression and 
ovarian cancer survival: an Ovarian Tumor 
Tissue Analysis consortium study. Lancet 
Oncol 2013; 14: 853-862.
[14] Slamon DJ, Clark GM, Wong SG, Levin WJ, 
Ullrich A and McGuire WL. Human breast can-
cer: correlation of relapse and survival with 
amplification of the HER-2/neu oncogene. 
Science 1987; 235: 177-182.
[15] Goldenberg MM. Trastuzumab, a recombinant 
DNA-derived humanized monoclonal antibody, 
a novel agent for the treatment of metastatic 
breast cancer. Clin Ther 1999; 21: 309-318.
[16] Piccart-Gebhart MJ, Procter M, Leyland-Jones 
B, Goldhirsch A, Untch M, Smith I, Gianni L, 
Baselga J, Bell R, Jackisch C, Cameron D, 
Dowsett M, Barrios CH, Steger G, Huang CS, 
Andersson M, Inbar M, Lichinitser M, Lang I, 
Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter 
TM, Ruschoff J, Suto T, Greatorex V, Ward C, 
Straehle C, McFadden E, Dolci MS, Gelber RD; 
Herceptin Adjuvant Trial Study T. Trastuzumab 
after adjuvant chemotherapy in HER2-positive 
breast cancer. N Engl J Med 2005; 353: 1659-
1672.
[17] Bookman MA, Darcy KM, Clarke-Pearson D, 
Boothby RA and Horowitz IR. Evaluation of 
monoclonal humanized anti-HER2 antibody, 
trastuzumab, in patients with recurrent or re-
fractory ovarian or primary peritoneal carcino-
ma with overexpression of HER2: a phase II 
trial of the Gynecologic Oncology Group. J Clin 
Oncol 2003; 21: 283-290.
[18] Anglesio MS, Kommoss S, Tolcher MC, Clarke 
B, Galletta L, Porter H, Damaraju S, Fereday S, 
Winterhoff BJ, Kalloger SE, Senz J, Yang W, 
Steed H, Allo G, Ferguson S, Shaw P, Teoman A, 
Garcia JJ, Schoolmeester JK, Bakkum-Gamez 
J, Tinker AV, Bowtell DD, Huntsman DG, Gilks 
CB and McAlpine JN. Molecular characteriza-
tion of mucinous ovarian tumours supports a 
stratified treatment approach with HER2 tar-
geting in 19% of carcinomas. J Pathol 2013; 
229: 111-120.
[19] McAlpine JN, Wiegand KC, Vang R, Ronnett 
BM, Adamiak A, Kobel M, Kalloger SE, 
Swenerton KD, Huntsman DG, Gilks CB and 
Miller DM. HER2 overexpression and amplifica-
tion is present in a subset of ovarian mucinous 
carcinomas and can be targeted with trastu-
zumab therapy. BMC Cancer 2009; 9: 433.
[20] Hammond MEH, Hayes DF, Dowsett M, Allred 
DC, Hagerty KL, Badve S, Fitzgibbons PL, 
[5] Siriaunkgul S, Robbins KM, McGowan L and 
Silverberg SG. Ovarian mucinous tumors of low 
malignant potential: a clinicopathologic study 
of 54 tumors of intestinal and mullerian type. 
Int J Gynecol Pathol 1995; 14: 198-208.
[6] Kehoe S and Powell J. Long-term follow-up of 
women with borderline ovarian tumors. Int J 
Gynaecol Obstet 1996; 53: 139-143.
[7] Martin LP and Schilder RJ. Management of re-
current ovarian carcinoma: current status and 
future directions. Semin Oncol 2009; 36: 112-
125.
[8] Despierre E, Yesilyurt BT, Lambrechts S, 
Johnson N, Verheijen R, van der Burg M, 
Casado A, Rustin G, Berns E, Leunen K, Amant 
F, Moerman P, Lambrechts D, Vergote I; EORTC 
GCG and EORTC GCG Translational Research 
Group. Epithelial ovarian cancer: rationale for 
changing the one-fits-all standard treatment 
regimen to subtype-specific treatment. Int J 
Gynecol Cancer 2014; 24: 468-477.
[9] Sinn BV, Darb-Esfahani S, Wirtz RM, Budczies 
J, Sehouli J, Chekerov R, Dietel M and Denkert 
C. Evaluation of a hormone receptor-positive 
ovarian carcinoma subtype with a favourable 
prognosis by determination of progesterone 
receptor and oestrogen receptor 1 mRNA ex-
pression in formalin-fixed paraffin-embedded 
tissue. Histopathology 2011; 59: 918-927.
[10] Darb-Esfahani S, Wirtz RM, Sinn BV, Budczies 
J, Noske A, Weichert W, Faggad A, Scharff S, 
Sehouli J, Oskay-Ozcelik G, Zamagni C, De Iaco 
P, Martoni A, Dietel M and Denkert C. Estrogen 
receptor 1 mRNA is a prognostic factor in ovar-
ian carcinoma: determination by kinetic PCR in 
formalin-fixed paraffin-embedded tissue. 
Endocr Relat Cancer 2009; 16: 1229-1239.
[11] Tangjitgamol S, Manusirivithaya S, Khunnarong 
J, Jesadapatarakul S and Tanwanich S. 
Expressions of estrogen and progesterone re-
ceptors in epithelial ovarian cancer: a clinico-
pathologic study. Int J Gynecol Cancer 2009; 
19: 620-627.
[12] Zhao D, Zhang F, Zhang W, He J, Zhao Y and 
Sun J. Prognostic role of hormone receptors in 
ovarian cancer: a systematic review and meta-
analysis. Int J Gynecol Cancer 2013; 23: 25-
33.
[13] Sieh W, Kobel M, Longacre TA, Bowtell DD, de-
Fazio A, Goodman MT, Hogdall E, Deen S, 
Wentzensen N, Moysich KB, Brenton JD, Clarke 
BA, Menon U, Gilks CB, Kim A, Madore J, 
Fereday S, George J, Galletta L, Lurie G, 
Wilkens LR, Carney ME, Thompson PJ, Matsuno 
RK, Kjaer SK, Jensen A, Hogdall C, Kalli KR, 
Fridley BL, Keeney GL, Vierkant RA, 
Cunningham JM, Brinton LA, Yang HP, Sherman 
ME, Garcia-Closas M, Lissowska J, Odunsi K, 
Morrison C, Lele S, Bshara W, Sucheston L, 
HER2-positive ovarian mucinous adenocarcinoma
4230 Int J Clin Exp Pathol 2014;7(7):4222-4230
[25] Hoerl HD and Hart WR. Primary ovarian muci-
nous cystadenocarcinomas: a clinicopatholog-
ic study of 49 cases with long-term follow-up. 
Am J Surg Pathol 1998; 22: 1449-1462.
[26] Bristow RE, Tomacruz RS, Armstrong DK, 
Trimble EL and Montz FJ. Survival effect of 
maximal cytoreductive surgery for advanced 
ovarian carcinoma during the platinum era: a 
meta-analysis. J Clin Oncol 2002; 20: 1248-
1259.
[27] Ozols RF. Systemic therapy for ovarian cancer: 
current status and new treatments. Semin 
Oncol 2006; 33: S3-11.
[28] Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, 
Ozols RF, Rose PG, Markman M, Armstrong 
DK, Muggia F, McGuire WP; Gynecologic 
Oncology Group Study. Prognostic factors for 
stage III epithelial ovarian cancer: a 
Gynecologic Oncology Group Study. J Clin 
Oncol 2007; 25: 3621-3627.
[29] Riopel MA, Ronnett BM and Kurman RJ. 
Evaluation of diagnostic criteria and behavior 
of ovarian intestinal-type mucinous tumors: 
atypical proliferative (borderline) tumors and 
intraepithelial, microinvasive, invasive, and 
metastatic carcinomas. Am J Surg Pathol 
1999; 23: 617-635.
[30] Watkin W, Silva EG and Gershenson DM. 
Mucinous carcinoma of the ovary. Pathologic 
prognostic factors. Cancer 1992; 69: 208-
212.
[31] Marsden DE, Friedlander M and Hacker NF. 
Current management of epithelial ovarian car-
cinoma: a review. Semin Surg Oncol 2000; 19: 
11-19.
[32] Rodriguez IM and Prat J. Mucinous tumors of 
the ovary: a clinicopathologic analysis of 75 
borderline tumors (of intestinal type) and carci-
nomas. Am J Surg Pathol 2002; 26: 139-152.
Francis G, Goldstein NS, Hayes M, Hicks DG, 
Lester S, Love R, Mangu PB, McShane L, Miller 
K, Osborne CK, Paik S, Perlmutter J, Rhodes A, 
Sasano H, Schwartz JN, Sweep FCG, Taube S, 
Torlakovic EE, Valenstein P, Viale G, Visscher D, 
Wheeler T, Williams RB, Wittliff JL and Wolff 
AC. American Society of Clinical Oncology/
College of American Pathologists Guideline 
Recommendations for Immunohistochemical 
Testing of Estrogen and Progesterone 
Receptors in Breast Cancer. J Clin Oncol 2010; 
28: 2784-2795.
[21] Wolff AC, Hammond MEH, Schwartz JN, 
Hagerty KL, Allred DC, Cote RJ, Dowsett M, 
Fitzgibbons PL, Hanna WM, Langer A, McShane 
LM, Paik S, Pegram MD, Perez EA, Press MF, 
Rhodes A, Sturgeon C, Taube SE, Tubbs R, 
Vance GH, de Vijver MV, Wheeler TM and Hayes 
DF; American Society of Clinical Oncology; 
College of American Pathologists. American 
Society of Clinical Oncology/College of 
American Pathologists guideline recommenda-
tions for human epidermal growth factor re-
ceptor 2 testing in breast cancer. J Clin Oncol 
2007; 25: 118-145.
[22] Vang R, Gown AM, Barry TS, Wheeler DT and 
Ronnett BM. Immunohistochemistry for estro-
gen and progesterone receptors in the distinc-
tion of primary and metastatic mucinous tu-
mors in the ovary: an analysis of 124 cases. 
Mod Pathol 2006; 19: 97-105.
[23] Wolff AC, Hammond MEH, Schwartz JN, 
Hagerty KL, Allred DC, Cote RJ, Dowsett M, 
Fitzgibbons PL, Hanna WM, Langer A, McShane 
LM, Paik S, Pegram MD, Perez EA, Press MF, 
Rhodes A, Sturgeon C, Taube SE, Tubbs R, 
Vance GH, de Vijver MV, Wheeler TM and Hayes 
DF; American Society of Clinical Oncology/
College of American Pathologists. American 
Society of Clinical Oncology/College of 
American Pathologists guideline recommenda-
tions for human epidermal growth factor re-
ceptor 2 testing in breast cancer. Arch Pathol 
Lab Med 2007; 131: 18-43.
[24] Lee KR and Scully RE. Mucinous tumors of the 
ovary: a clinicopathologic study of 196 border-
line tumors (of intestinal type) and carcino-
mas, including an evaluation of 11 cases with 
‘pseudomyxoma peritonei’. Am J Surg Pathol 
2000; 24: 1447-1464.
